Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Advanced or Metastatic Solid Tumors 1

Interventions

pembrolizumab 41Injections 39toripalimab 23Nivolumab 22Cisplatin 19Pemetrexed 18Carboplatin 18Cyclophosphamide 17Paclitaxel 14Bevacizumab 14fludarabine 12Gemcitabine 11tislelizumab 10Ipilimumab 10spartalizumab 9Irinotecan 9atezolizumab 8Docetaxel 8Oxaliplatin 7Leucovorin 7Fluorouracil 7Capecitabine 6sintilimab 5Interleukin-2 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5trifluridine tipiracil drug combination 4sotorasib 4pazopanib 4palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × TAK-981 × Other solid neoplasm × Clear all
NCT04381650 2025-12-10

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Takeda

Phase 1/2 Completed
161 enrolled 44 charts
Other solid neoplasm

Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡